

Sheet 1 of 3

Substitute for form 1449/PTO  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  MAY 30 2003 PARENT & TRANSLATE		ATTY DOCKET NO.. <b>8321-0115 (37075-179015)</b>	SERIAL NO. <b>09/816,513</b>
APPLICANT <b>Bernard Dietzschold et al.</b>		JUN 04 2003 TECH CENTER 1600/2900	
FILING DATE <b>March 23, 2001</b>		GROUP <b>1648</b>	

## U.S. PATENT DOCUMENTS

EXR. INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
W	AA 5,853,735	12/29/1998	Benejean et al.	424	208.1	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA TION YES	NO
W	AB WO 01/70932	9/27/01	WO	C12N			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Allen and Seed (1989) <i>Science</i> 243:378-80
AD	Berg et al. (1995) <i>J. Clin. Invest.</i> 96:2339-2347
AE	Bogdan et al. (1991) <i>J. Exp. Med.</i> 174:1549-1555
AF	Carrera et al. (1996) <i>J. Exp. Med.</i> 183:515-526
AG	Cassatella et al. (1989) <i>J. Exp. Med.</i> 169:549-567
AH	Chattergoon et al. (2000) <i>Nat. Biotech.</i> 18: 974-979
AI	Chehimi et al. (1994) <i>J. Exp. Med.</i> 179:1361-1366
AJ	Cohn et al. (1946) <i>J. Am. Chem. Soc.</i> 68:459-475
AK	Conzelman (1998) <i>Ann. Rev. Genet.</i> 32: 123-162
AL	Dalrymple et al. (1995) <i>Infect. Immun.</i> 63:2262-2268
AM	D'Andrea et al. (1993) <i>J. Exp. Med.</i> 178:1041-1048
AN	Davidson et al. (1996) <i>J. Exp. Med.</i> 184:241-251
AO	Dietzschold et al. (1983) <i>Proc. Natl. Acad. Sci. USA</i> 80:70-74
AP	Dietzschold et al. (1985) <i>J. Virol.</i> 56: 12-18
AQ	Dietzschold et al. (1999) <i>Molecular Pathogenesis of Rabies</i> , Abstract Presentation, 10 <sup>th</sup> Annual Rabies in Americas, Nov. 14-19, San Diego, CA
AR	Dietzschold et al. (2000) <i>J. Human Virol.</i> 3:50-57
AS	Faber et al. (2002) <i>J. Virol.</i> 76: 3374-3381
AT	Finke et al. (2000) <i>J. Virol.</i> 74: 7261-7269

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

Sheet 2 of 3

Substitute for form 1449/PTO  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  MAY 30 2003		ATTY DOCKET NO. 8321-0115 (37075-179015)	SERIAL NO. 09/816,513
		APPLICANT Bernard Dietzschold <i>et al.</i>	JUN 04 2003 TECH CENTER 1600/2900
		FILING DATE March 23, 2001	GROUP 1648

AU	Fiorentino <i>et al.</i> (1991) <i>J. Immunol.</i> 146:3444-3451
AV	Galelli <i>et al.</i> (2000) <i>J. Neurovirol.</i> 6: 359-372
AW	Gavin <i>et al.</i> (1998) <i>J. Immunol.</i> 160:20-23
AX	Germann <i>et al.</i> (1995) <i>Proc. Natl. Acad. Sci. USA</i> 92:4823-4827
AY	Hale <i>et al.</i> (1988) <i>Lancet</i> 2:1394-1399
AZ	Hart <i>et al.</i> (1995) <i>Immunol.</i> 84:536-542
BA	Hazenbos <i>et al.</i> (1996) <i>Immunity</i> 5:181-188
BB	Heinzel <i>et al.</i> (1993) <i>J. Exp. Med.</i> 177:1505-1512
BC	Howard <i>et al.</i> (1993) <i>J. Exp. Med.</i> 177:1205-1208
BD	Jallet <i>et al.</i> (1999) <i>J. Virol.</i> 73: 225-233
BE	Jones <i>et al.</i> (1986) <i>Nature</i> 321:522-525
BF	Karp <i>et al.</i> (1996) <i>Science</i> 273:228-231
BG	Kincy-Cain <i>et al.</i> (1996) <i>Infect. Immun.</i> 64:1437-1440
BH	Kleinveld <i>et al.</i> (1988) <i>Scand. J. Rheumatology</i> 75:157-163
BI	Kothakota <i>et al.</i> (1997) <i>Science</i> 278: 294-297
BJ	Kunkel <i>et al.</i> (1988) <i>J. Biol. Chem.</i> 263:5380-5384
BK	Lee <i>et al.</i> (1988) <i>J. Chromatography</i> 444:141-52
BL	Leonard <i>et al.</i> (1995) <i>J. Exp. Med.</i> 181:381-386
BM	Malefyt <i>et al.</i> (1991) <i>J. Exp. Med.</i> 174:1209-1220
BN	Malefyt <i>et al.</i> (1991) <i>J. Exp. Med.</i> 174:915-924
BO	Mattner <i>et al.</i> (1996) <i>Eur. J. Immunol.</i> 26:1553-1559
BP	Mebatsion <i>et al.</i> (1995) <i>J. Virol.</i> 69(3):1444-1451
BQ	Mebatsion <i>et al.</i> (1996) <i>Proc. Natl. Acad. Sci. USA</i> 93(21):11366-11370
BR	Morimoto <i>et al.</i> (1996) <i>Proc. Natl. Acad. Sci. USA</i> 93:5653-5658
BS	Morimoto <i>et al.</i> (1999) <i>J. Virol.</i> 73: 510-517
BT	Morimoto <i>et al.</i> (2000) <i>J. Neurovirol.</i> 6: 373-381
BU	Morimoto <i>et al.</i> (2001) <i>Vaccine</i> 19:3543-3551
BV	Muta <i>et al.</i> (1994) <i>Nature</i> 368:70-73
BW	Nathan (1987) <i>J. Clin. Invest.</i> 79:319-326

EXAMINER



DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Sheet 3 of 3

<p style="text-align: center;"><b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b></p> <p style="text-align: right;">MAY 30 2003</p>	<b>ATTY DOCKET NO..</b>	<b>SERIAL NO.</b>
	8321-0115 (37075-179015)	09/816,581
	<b>APPLICANT</b>	<b>JUN 04 2003</b>
	Bernard Dietzschold <i>et al.</i>	
<b>FILING DATE</b>	<b>GROUP</b>	
March 23, 2001	1646 TECH CENTER 1600/2900	

BX	Noel <i>et al.</i> (1992) <i>J. Infect. Dis.</i> 166:178-182
BY	Oncley <i>et al.</i> (1949) <i>J. Am. Chem. Soc.</i> 71:541-550
BZ	Pulmanausahakul <i>et al.</i> (2001) <i>J. Virol.</i> 75(22): 10800-10807
CA	Queen <i>et al.</i> (1989) <i>Proc. Natl. Acad. Sci. USA</i> 86:10029-10033
CB	Reid <i>et al.</i> (1997) <i>J. Immunol.</i> 159:970-975
CC	Reiner <i>et al.</i> (1993) <i>J. Immunol. Methods</i> 165:37-46
CD	Restifo (2000) <i>Curr. Opin. Immunol.</i> 12: 597-603
CE	Rovere <i>et al.</i> (1998) <i>J. Immunol.</i> 161: 4467-4471
CF	Sasaki <i>et al.</i> (2001) <i>Nat. Biotech.</i> 19: 543-547
CG	Schnell <i>et al.</i> (1999) <i>Recombinant Rabies Virus as Potential Live-Viral Vaccines for HIV-1</i> , Abstract Presentation, 10 <sup>th</sup> Annual Rabies in the Americas, Nov. 14-19, San Diego, CA
CH	Sears <i>et al.</i> (1990) <i>J. Immunol.</i> 144:371-78
CI	Shi <i>et al.</i> (2000) <i>Proc. Natl. Acad. Sci. USA</i> 97: 14590-14595
CJ	Sutterwala <i>et al.</i> (1997) <i>J. Exp. Med.</i> 185:1977-1985
CK	Sutterwala <i>et al.</i> (1996) <i>J. Leukocyte Biol.</i> 59:883-890
CL	Takai <i>et al.</i> (1994) <i>Cell</i> 76:519-529
CM	Takai <i>et al.</i> (1996) <i>Nature</i> 379:346-349
CN	Tankersley (1994) <i>Immunol. Reviews</i> 139:159-172
CO	Trembleau <i>et al.</i> (1995) <i>J. Exp. Med.</i> 181:817-821.
CP	Trinchieri <i>et al.</i> (1996) <i>J. Leukocyte Biol.</i> 59:505-511
CQ	Tripp <i>et al.</i> (1993) <i>Proc. Natl. Acad. Sci. USA</i> 90:3725-3729
CR	Tsunawaki <i>et al.</i> (1988) <i>Nature</i> 334:260-262
CS	Verhoeven <i>et al.</i> (1988) <i>Science</i> 239:1534-1536
CT	Vialtel <i>et al.</i> (1982) <i>J. Biol. Chem.</i> 257:3811-3818
CU	Virag <i>et al.</i> (1998) <i>Immunol.</i> 94: 345-355
CV	Wiktor (1977) <i>Proc. Natl. Acad. Sci. USA</i> 74: 334-338
CW	Wright <i>et al.</i> (1980) <i>Biochem J.</i> 187:767-774
CX	Wysocka <i>et al.</i> (1995) <i>Eur. J. Immunol.</i> 25:672-676
CY	Yan <i>et al.</i> (2001) <i>J. Neurovirol.</i> 7: 518-527

EXAMINER 	DATE CONSIDERED 
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	